awmsg logo



tegafur/gimeracil/oteracil (Teysuno®)


Reference No. 928

Publication date:
03/12/2013


Appraisal information

tegafur/gimeracil/oteracil (Teysuno®) 15 mg/4.35 mg/11.8 mg capsule
tegafur/gimeracil/oteracil (Teysuno®) 20 mg/5.8 mg/15.8 mg capsule


Company: Nordic Pharma UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/09/2013
AWMSG meeting date: 16/10/2013
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2613
Ministerial ratification: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tegafur/gimeracil/oteracil (Teysuno®) is recommended as an option for restricted use within NHS Wales in adults for the treatment of advanced gastric cancer when given in combination with cisplatin, when standard triplet therapy is not suitable.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download